Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends aripiprazole

NICE's FAD recommends the use of Bristol-Myers Squibb's atypical anti-psychotic drug Abilify (aripiprazole) as an option for the treatment of adolescent schizophrenia

The National Institute for Health and Clinical Excellence's (NICE) Final Appraisal Determination (FAD) has recommended the use of Abilify (aripiprazole) as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.

Aripiprazole received its first EU approval in 2004. In the UK it is the only commonly-used atypical anti-psychotic licensed for the treatment of adolescent schizophrenia and the first to be appraised by NICE.

The announcement of NICE's forthcoming guidance, which will offer patients in the UK access to a cost-effective treatment for their condition, has been welcomed by patient groups.

According to Marjorie Wallace, CBE, chief executive of mental health charity, SANE: "Everyone's biochemistry differs and the more we can find a choice of medications to target individual needs, with side-effects that can be tolerated, the more we can help people to manage their condition."

"This is particularly important in teenagers: schizophrenia often strikes at this time and it is vital to find effective treatment and prevent relapse, With better medications and therapies, the lives of young people with schizophrenia can be greatly improved," Wallace said.

1st December 2010

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics